Pfizer's (PFE.US) $43 billion Seagen (SGEN.US) deal wins unconditional EU approval. As it was concluded by European lawmakers, deal wouldn't raise competition concerns or higher prices for oncology drugs.
Source: xStation5
Amazon shares tumble 10% as investors recoil at the price of AI dominance
Disaster for Volvo shares. Is this the end of an iconic brand?
Stock of the week: Alphabet is no longer just a search engine (05.02.2026)
🚨US100 loses 2% amid US technology stocks sell-off